Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. - Wikidata - awgldk - TriplyDB

Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review.

Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review.

http://www.wikidata.org/entity/Q34984056

about

Viral hepatitis and hepatocellular carcinoma Hepatitis C: a review for primary care physicians Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis.Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma.Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis.Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIα in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma.Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits.APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review.Management of chronic hepatitis C.Unnecessary repeat requesting of tests: an audit in a government hospital immunology laboratory Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma.Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development.Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C.An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer.Serum biomarkers identification by mass spectrometry in high-mortality tumors.Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma.Use of Biomarkers in Screening for Cancer.Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review.Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors.Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm.Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity.Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma.A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers.In vivo and in vitro effect of hepatocarcinoma lymph node metastasis by upregulation of Annexin A7 and relevant mechanisms.Simplified HCC-ART score for highly sensitive detection of small-sized and early-stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems.The Presence of Portal Vein Thrombosis Alters the Classic Enhancement Associated with Diagnosis of Hepatocellular Carcinoma.The optimal follow-up period in patients with above 5-year disease-free survival after curative liver resection for hepatocellular carcinoma Prediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method.The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies.Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein.

P2860

Q21245597-570D2CEA-267F-45D9-B9B2-2317A69B6F0F Q22306040-B6B706B2-8C3F-45D6-8C35-316B5F27607F Q28085015-96CCA0FA-5DD7-4DA7-9A32-D9AF5B418BEB Q30479629-A276E22B-F54C-4B7F-A808-FA4B0B363C38 Q33272872-F0C7A36C-8733-44E4-B4D2-7F3409A016F3 Q33493776-6EB7913C-E2D9-4011-9E72-3228137414AB Q33728371-D4989881-A13C-44E0-B675-221D36E9EA66 Q34325161-19D6B99F-A391-49CC-A686-E930CBDE47EA Q34461237-5EE0AC75-05FA-411A-935D-0933160BFAB7 Q34660116-80F55CAA-6617-463A-9BAB-317859ABC78A Q34979196-1B6C2FEB-81DA-4920-87E0-9B6AC8A1AE7B Q35010543-81767CFE-5BEA-4A68-A892-823F8A426191 Q35207736-0C4443F2-9852-4676-AA3F-0CDB69676218 Q35522138-812ACFE2-A8C1-476D-A2EB-296796F864B5 Q35588517-8DB517D6-5759-45EB-ACA2-18C47912D553 Q35633563-9D1AB289-7BCC-493E-BA62-D22CB4ADF13F Q36033548-0FB4DDCD-25B3-482B-AB5B-7686A4F5E34F Q36194266-96157AD5-2EC3-4568-9848-BE9DCD8685FD Q36459759-A692421B-62C6-40DB-81EC-EE0652277916 Q36476387-F355B54C-FEC9-4CAF-B582-FC44AC23A226 Q36582422-BBE59ACF-4000-4F77-B8E9-B3D1DCA73E92 Q36731844-FEB3761F-A074-4634-869A-31E9E8864A76 Q37155019-772C232A-7DE9-4534-B57C-F8048A50F0A5 Q37235449-65064A6F-9E8E-4DD9-A970-6780F7C1DDB7 Q37246570-F8BED5EC-083E-465A-88E4-99FA110AE254 Q37266376-26F9279E-6A4E-4A80-9E32-7F811409B357 Q37577551-7D1F00C5-E6AF-42A7-AB99-A505D941E285 Q37724875-A2E8C7F6-3A26-49F7-8DD2-D11054F61CE9 Q38279464-3C6862CD-5D9B-49DC-9423-70ED2B2F516E Q38482765-05CBB04A-9777-4DDD-A97E-E2E1C86E297F Q38560093-2619FA33-699E-4311-9FBC-CD45394F6577 Q38686490-0DD0B784-9E0D-4157-9AC1-1DB066D78F23 Q38845150-9039E3CF-CB44-405B-A60B-528837D6F75E Q38883230-8CCF7868-F956-4715-8CEC-6F38FDCCD43C Q41208415-CCA4600B-8112-4F74-9463-1314958E06B3 Q42783674-EA3432F7-EFA2-4B3F-989E-409EA07741F4 Q42954755-A231F8A6-CA5E-4507-9DEC-6CD6D0507472 Q43108443-7DD6DCDA-E1F7-4848-A849-2F49865E74FD Q43806466-AAF6A632-BC78-4D40-AE38-D63DEF128A52 Q44930583-0605CCB5-B5AD-4900-9694-CFFBA414A3CE

P2860

Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review.

http://www.wikidata.org/entity/Q34984056

description

2002 nî lūn-bûn

@nan

2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Screening tests for hepatocell ...... atitis C: a systematic review.

@ast

Screening tests for hepatocell ...... atitis C: a systematic review.

@en

Screening tests for hepatocell ...... atitis C: a systematic review.

@nl

type

label

Screening tests for hepatocell ...... atitis C: a systematic review.

@ast

Screening tests for hepatocell ...... atitis C: a systematic review.

@en

Screening tests for hepatocell ...... atitis C: a systematic review.

@nl

prefLabel

Screening tests for hepatocell ...... atitis C: a systematic review.

@ast

Screening tests for hepatocell ...... atitis C: a systematic review.

@en

Screening tests for hepatocell ...... atitis C: a systematic review.

@nl

P1433

Q34984056-7C7700A3-0142-4CC2-A1C1-96CCD47FE423

P1476

Q34984056-86D52C02-BAC3-4148-8007-F80B4918FFA5

P2093

Q34984056-096552FA-A16B-495C-A638-7331AB2E38E9

Q34984056-173BF918-9AF6-42E9-9439-8EE91FA6C698

Q34984056-28D4ADA1-3E0A-4403-9D62-DB98E8788772

Q34984056-2E3EACEE-EF9E-4C92-9D19-25DA1EA2A9D0

Q34984056-BC0AB0CB-9722-40EC-9BAC-282CB84E0B49

Q34984056-D03E6C2F-FD55-4751-BE75-5E676F7F6C0E

Q34984056-D49716DD-CC01-4FB7-87E3-A7B07E2392DB

Q34984056-DC278C20-65F3-47A3-AA72-A8E4A75F6A8A

P2860

Q34984056-0AE8CF67-85E5-4085-A8A4-4C4D0158AABD

Q34984056-14C7999D-110F-451F-93BA-75BE065DF416

Q34984056-1F0BF27B-4A88-4ADA-A643-B25A741B9C94

Q34984056-2461E3D3-C163-44E0-8D47-834380994619

Q34984056-37C8B1B4-CDB4-421B-954A-FEA37F4AEB2C

Q34984056-57A831A7-B97C-4375-8D15-8FBB56196CCF

Q34984056-591DD3D3-CE0E-43FC-832C-9D8621F93935

Q34984056-649ADB1C-BC96-43B9-8F47-AF7B1058D81E

Q34984056-64A41F88-54CB-4D85-AD5B-397B7F014900

Q34984056-6E70043B-5769-4702-AACA-2FF1AF3CE1CA

P304

Q34984056-83675463-2AC3-4506-AE5D-29D3BDC11955

P31

Q34984056-CB3BB7E2-0701-41E3-AE32-18E9B1B1B035

P356

Q34984056-904B5882-83FD-4327-82C4-B140D34C60FE

P407

Q34984056-CCA2A6C3-A145-4ABC-8475-E2B5A52657E3

P433

Q34984056-EE4D7FF7-076F-4B3A-A641-8C3BCC61ED7D

P478

Q34984056-1DDE2131-4C1F-4897-9B2D-DC128D87EEA1

P577

Q34984056-2F763C84-1AAA-42F6-A70C-B11D1E135B82

P5875

Q34984056-C5E42F58-0A9D-43F3-BF34-C029C50C91E8

P698

Q34984056-F20517D2-2AAC-4FA5-BEA1-00797DCE198F

P356

JHEP.2002.36817

P1433

P1476

Screening tests for hepatocell ...... atitis C: a systematic review.

@en

P2093

Eric B Bass

http://www.w3.org/2001/XMLSchema#string

Geetanjali Chander

http://www.w3.org/2001/XMLSchema#string

H Franklin Herlong

http://www.w3.org/2001/XMLSchema#string

Kelly A Gebo

http://www.w3.org/2001/XMLSchema#string

Khalil G Ghanem

http://www.w3.org/2001/XMLSchema#string

Michael S Torbenson

http://www.w3.org/2001/XMLSchema#string

Mollie W Jenckes

http://www.w3.org/2001/XMLSchema#string

Samer S El-Kamary

http://www.w3.org/2001/XMLSchema#string

P2860

Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease

Pharmacological treatment of alcohol dependence: a review of the evidence.

Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.

Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C.

Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma

Elevation of cytokeratin 19 fragment in serum in patients with hepatoma: its clinical significance.

Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients.

Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients.

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study.

Urinary transforming growth factor beta1 levels in hepatitis C virus-related chronic liver disease: correlation between high levels and severity of disease.

P304

S84-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JHEP.2002.36817

http://www.w3.org/2001/XMLSchema#string

P407

P433

5 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11056237

http://www.w3.org/2001/XMLSchema#string

P698

12407580

http://www.w3.org/2001/XMLSchema#string